Intercept Pharmaceuticals (NASDAQ:ICPT) will release its earnings data before the market opens on Wednesday, August 7th. Analysts expect Intercept Pharmaceuticals to post earnings of ($2.51) per share for the quarter. Intercept Pharmaceuticals has set its FY 2019 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) EPS for the quarter, missing the consensus estimate of ($2.57) by ($0.46). Intercept Pharmaceuticals had a negative net margin of 162.49% and a negative return on equity of 617.23%. The firm had revenue of $52.25 million during the quarter, compared to analyst estimates of $52.15 million. During the same period in the previous year, the company posted ($3.22) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 45.3% compared to the same quarter last year. On average, analysts expect Intercept Pharmaceuticals to post $-10 EPS for the current fiscal year and $-9 EPS for the next fiscal year.
Intercept Pharmaceuticals stock opened at $59.71 on Tuesday. Intercept Pharmaceuticals has a 12 month low of $58.21 and a 12 month high of $133.74. The company has a 50 day moving average price of $73.08. The company has a quick ratio of 3.72, a current ratio of 3.72 and a debt-to-equity ratio of 19.41. The firm has a market capitalization of $1.78 billion, a P/E ratio of -5.50 and a beta of 1.32.
Several research firms have recently commented on ICPT. Stifel Nicolaus began coverage on Intercept Pharmaceuticals in a research report on Monday, June 24th. They issued a “hold” rating and a $89.00 target price on the stock. BidaskClub downgraded Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 26th. Wedbush set a $243.00 price target on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, July 5th. Oppenheimer reduced their price target on Intercept Pharmaceuticals from $175.00 to $170.00 in a research report on Monday, April 29th. Finally, ValuEngine raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $142.00.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Recommended Story: What are the most popular ETFs
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.